Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01203943 · ClinicalTrials.gov registry record · Phase 2
A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)
A Phase 2 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT01203943 is a Phase 2 study that was terminated before completion, run by Celgene. The registered enrollment target is 28 participants.
The verdict
NCT01203943, a Phase 2 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.
Interventions
- OTHER Placebo
- DRUG CC-930
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-01-01 |
| Est. Completion | 2012-08-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01203943
The ClinicalTrials.gov registry entry for NCT01203943 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01203943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01203943 about?
NCT01203943 is a clinical study titled "A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)". The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.
What is the current status of trial NCT01203943?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2011-01-01. Estimated completion is 2012-08-24.
What interventions are being tested in trial NCT01203943?
The interventions under investigation include: Placebo (OTHER), CC-930 (DRUG).
Who is sponsoring clinical trial NCT01203943?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.